Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Shares in Supernus Pharmaceuticals (NASDAQ:SUPN) jumped by 10% earlier today after SunTrust Robinson Humphrey initiated coverage on the company with a buy rating.
So What: First things first, investors should always take analyst ratings with a grain of salt and focus instead on their own due diligence before jumping in and buying shares, especially in the highly volatile biotechnology industry.
In the case of Supernus Pharmaceuticals, however, analysts may be onto something.
The company already markets two compounds, Trokendi XR and Oxteller XR, that are used to treat epilepsy, and those drugs had combined sales of $28.1 million in the first quarter, up from just $9 million a year ago.Revenue growth was due in large part to prescriptions of Trokendi XR increasing by 187% year-over-year and by 14% quarter-of-quarter.
Because Supernus Pharmaceuticals was able to leverage rising script volume against fixed costs, EPS came in at $0.02 in the first quarter, leading the company to reaffirm guidance for full year sales of between $130 million and $140 million and operating income of between $6 million and $10 million.
Now What: The profit forecast comes even as the company is investing significantly more into the development of its product pipeline, which includes two therapies for the treatment of ADHD.
Supernus Pharmaceuticals estimates that costs associated with a phase 3 trial of SPN-810 for impulsive aggression in ADHD patients and a phase 2 trial for SPN-812 for ADHD -- both of which are slated to begin in the fourth quarter -- will push its spending on R&D up 50% this year.
If the company can continue to drive script volume higher, it should be able to digest the planned spending increases, and if so, then this company may be worth keeping on investors' radar -- especially given that forecasts suggest that its EPS could expand from $0.13 this year to $0.78 next year.
Todd Campbell has no position in any stocks mentioned. Todd owns E.B. Capital Markets, LLC. E.B. Capital's clients may have positions in the companies mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
Why Supernus Pharmaceuticals Inc. Is Having a Rather Non-Super Day
Despite Supernus' strong third-quarter earnings report, two possible concerns send the stock tumbling.
Why Supernus Pharmaceuticals' Shares Plummeted 23.4% Today
A change to phase 3 trials evaluating its lead product candidate SPN-810 fueled investors' pessimism.
3 Growth Stocks for Sharp Investors
On the hunt for a few stocks that hold upside potential? Here's why you should consider Starbucks, Wynn Resorts, and Supernus Pharmaceuticals.